News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 217–228 of 243 stories
Funding & Grants8 Sept 2026

OutSee Awarded Innovate UK Grant for Agentic AI Target Validation Pilot

OutSee has been awarded a £50,000 grant, jointly funded by Innovate UK and Empirical Ventures through the Investor Partnership Growth Catalyst programme, plus matching investment. The funding will support a pilot study to build a prototype agentic AI sub-system for initial triage of drug targets identified by Nomaly, OutSee's predictive genomics platform, aiming to remove a manual validation bottleneck currently handled by its scientific team.

SilviBio to Break Ground on First Peat-Free Production Plant in Scotland

SilviBio is preparing to break ground on its first production facility in Scotland, moving its peat and coir-free growing media from pilot scale to commercial volumes ahead of the early 2027 growing season. The Livingston-based company makes its products entirely from UK-sourced materials including sheep's wool, and its technology was developed with support from IBioIC through the Innovate UK-led Scottish Bio-based Manufacturing Launchpad.

Stevenage Bioscience Catalyst appoints Andrew Waters as CEO

Stevenage Bioscience Catalyst's board has appointed Andrew Waters as Chief Executive Officer, promoting him from Chief Financial Officer & Interim CEO, a role he had held since January 2025. Waters joined SBC as CFO in September 2023 after 16 years at GSK across R&D and commercial roles and six years co-founding a start-up that raised over £40 million and launched OTC medicines into the US market.

C4X Discovery receives $13m AstraZeneca clinical milestone payment

C4X Discovery will receive a $13 million milestone payment from AstraZeneca, triggered by the entry of its licensed oral NRF2 activator programme (AZD4916) into a Phase I clinical trial. Under the 2022 licensing agreement, C4XD is potentially eligible for up to $400 million in preclinical, development and commercial milestones plus tiered royalties on future sales; AZD4916 is being developed for inflammatory and respiratory diseases.

Funding & Grants4 Sept 2026

Nascent Therapeutics raises £750k led by Zinc, with Medicines Discovery Catapult

Nascent Therapeutics, a University of East Anglia spinout, has secured £750,000 led by Zinc Venture Capital with Medicines Discovery Catapult co-investing, the latter funded via Innovate UK. The funding will advance Nascent's platform regulating mitochondrial transfer between cells, initially targeting Parkinson's disease, with the company's founding work having earlier been supported by £75,000 from UEA's MRC Impact Accelerator Account and a £50,000 UEA Innovation Development Award.

Funding & Grants4 Sept 2026

Flip Therapeutics receives £500k from Medicines Discovery Catapult

Flip Therapeutics has received £500,000 from Medicines Discovery Catapult, funded via Innovate UK, alongside translational drug discovery expertise and access to MDC's advisor network. The investment supports validation of Flip's in vivo T cell reprogramming payloads and their integration with nanoparticle delivery technology, aimed at chronic autoimmune and inflammatory diseases including alopecia areata and psoriasis.

Nxera Pharma to Receive $8.6m Milestone Payment from Centessa

Nxera Pharma will receive an $8.6 million milestone payment from Centessa Pharmaceuticals, now a wholly-owned subsidiary of Eli Lilly, after Centessa reached a late-stage development milestone in its selective orexin receptor 2 agonist portfolio. The payment is triggered under Nxera's research collaboration with Centessa and will be recognised as revenue in the third quarter of the year ending 31 December 2026.

John Innes Centre secures first UK marketing notice for precision-bred tomato

John Innes Centre has secured England's first marketing notice for a precision-bred tomato, approving its biofortified "Sunshine" variety under Defra's Precision Bred Organism framework. Developed by Professor Cathie Martin's team using CRISPR-Cas9 to knock out a gene involved in vitamin D3 breakdown, the tomato accumulates high levels of pro-vitamin D3 in its fruit and leaves; it still needs Food Standards Agency approval before it can reach shops.

Tangram Therapeutics advances TGM-312 to MASH patient cohorts, appoints CDO

Tangram Therapeutics has progressed its MASH candidate TGM-312 into Part B (multiple ascending dose, patient cohorts) of its Phase 1/2 RESTORE-MASH trial, following favourable independent Data Monitoring Committee review and four healthy-volunteer cohorts with no serious or severe adverse events; interim patient data are expected during 2027. The company also appointed Dr Sonya Montgomery, previously Chief Development Officer at OSE Immunotherapeutics and Chief Medical Officer at Evox Therapeutics, as Chief Development Officer to lead its clinical pipeline.

Oxford BioDynamics platform links five fatigue-related conditions

Oxford BioDynamics' EpiSwitch Orion platform has identified shared 3D genome regulatory networks across five distinct fatigue-related conditions — ME/CFS, long COVID, PTSD, rheumatoid arthritis, and multiple sclerosis — in a peer-reviewed study led by the University of East Anglia. Despite almost no overlap at the individual gene level, the conditions converged on common immune, inflammatory, metabolic, and neuroendocrine circuitry, demonstrating Orion's ability to surface biological insights from existing genomic data.

OptiBiotix's SlimBiome launches in Holland & Barrett's new FORMI range

Holland & Barrett has launched FORMI, a new own-brand weight management line, with its first product containing OptiBiotix Health's SlimBiome formulation. The launch builds on a three-year non-exclusive trademark licence agreement signed in December 2025 and targets consumers seeking non-drug weight management options, including those who don't tolerate or have completed GLP-1 treatment.